BPC-157 vs TB-500: Research Considerations
Two of the most-studied research peptides, side by side — structure, mechanism, stability, and the laboratory research questions each is best suited for.
Overview
BPC-157 and TB-500 are two of the most studied peptides in laboratory research settings. While both are frequently used in tissue-repair models, they have distinct molecular structures, mechanisms of action, and research applications. This guide compares their key characteristics side-by-side and links out to the primary literature for each.
BPC-157
Full Name:
Body Protection Compound-157
Sequence:
15 amino acids
Molecular Formula:
C₆₂H₉₈N₁₆O₂₂
Origin:
Synthetic peptide derived from gastric juice protein
TB-500
Full Name:
Thymosin Beta-4 Fragment
Sequence:
43 amino acids
Molecular Formula:
C₂₁₂H₃₅₀N₅₆O₇₈S
Origin:
Synthetic version of naturally occurring thymosin beta-4
Research Applications
BPC-157 Research Focus
- •Gastrointestinal tissue studies
- •Vascular system research
- •Cellular protection mechanisms
- •Tissue repair pathway investigation
TB-500 Research Focus
- •Cell migration and differentiation studies
- •Actin protein interaction research
- •Angiogenesis pathway investigation
- •Wound healing mechanism studies
Side-by-Side Comparison
The table below summarizes the structural, biophysical, and research-application differences that matter most when designing in-vitro experiments with either peptide.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Full name | Body Protection Compound-157 | Thymosin Beta-4 fragment |
| Length | 15 amino acids (pentadecapeptide) | 43 amino acids |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ | C₂₁₂H₃₅₀N₅₆O₇₈S |
| Approx. molecular weight | ~1419 Da | ~4960 Da |
| Origin | Synthetic fragment of a gastric-juice protein | Synthetic active fragment of thymosin β-4 |
| Primary research focus | GI tissue repair models, vascular signaling, growth-factor modulation | Actin sequestration, cell migration, angiogenesis pathways |
| Notable mechanism | Studied for VEGFR2 / NO-pathway interactions in injury models | G-actin binding via N-terminal LKKTET motif |
| Solubility (typical) | Water-soluble; bacteriostatic water common | Water-soluble; sensitive to repeated freeze-thaw |
| Stability in solution | Comparatively robust; shorter chain less aggregation-prone | Larger chain — aliquot to minimize freeze-thaw cycles |
| Recommended storage | Lyophilized at -20 °C; reconstituted at 2-8 °C short-term | Lyophilized at -20 °C; reconstituted at 2-8 °C short-term |
| Primary literature anchors | Sikiric et al., 2010; Sikiric et al., 2016 | Goldstein et al., 2012; Crockford et al., 2010 |
Mechanism summaries reflect how each peptide is described in the cited literature. They are not statements of clinical effect and do not imply human-use indications.
Practical Notes for Bench Work
Both peptides are typically supplied as lyophilized white powders and reconstituted with bacteriostatic or sterile water in a laminar flow hood. Because their molecular weights differ by roughly 3.5x, working concentrations from published literature can't be transferred between them without re-deriving the molarity. Always verify the lot-specific Certificate of Analysis and net peptide content before calculating stock concentrations — especially for TB-500, where a TFA salt can shift the effective peptide weight several percent. For background on what purity numbers mean in this context, see our guide on peptide purity standards.
References
- Sikiric P, Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review). Current Pharmaceutical Design, 2010; 16(10): 1224-1234.
- Sikiric P, Seiwerth S, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 2016; 14(8): 857-865.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012; 12(1): 37-51.
- Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 2010; 1194: 179-189.
- Huff T, Müller CSG, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. International Journal of Biochemistry & Cell Biology, 2001; 33(3): 205-220.
References are listed for educational purposes only. Citation of any publication, regulatory document, or industry standard does not imply endorsement and should not be interpreted as medical advice or as instructions for human, veterinary, or in-vivo use of any peptide.
Research Use Only
Both BPC-157 and TB-500 are intended for laboratory research use only. They are not approved for human consumption, veterinary use, food, drug, diagnostic, therapeutic, or cosmetic applications. All research should be conducted by qualified researchers in appropriate laboratory settings.
Frequently Asked Questions
Are BPC-157 and TB-500 the same thing?
No. BPC-157 is a synthetic 15-amino-acid sequence derived from a gastric protein, while TB-500 is a synthetic version of thymosin beta-4, a 43-amino-acid peptide. They have different sizes, structures, and research mechanisms.
Which is bigger, BPC-157 or TB-500?
TB-500 is roughly three times the size of BPC-157 — 43 amino acids vs 15. The size difference influences solubility, stability in solution, and synthesis difficulty.
Can BPC-157 and TB-500 be used together in research?
Some published research has investigated both peptides in parallel or combined research models. Specific protocols depend on the experimental design and should be drawn from primary literature.